These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 28643901)
1. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Trenkwalder C; Winkelmann J; Oertel W; Virgin G; Roubert B; Mezzacasa A; Mov Disord; 2017 Oct; 32(10):1478-1482. PubMed ID: 28643901 [TBL] [Abstract][Full Text] [Related]
2. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome. Schneider J; Krafft A; Manconi M; Hübner A; Baumann C; Werth E; Gyr T; Bassetti C Sleep Med; 2015 Nov; 16(11):1342-1347. PubMed ID: 26498233 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial. Earley CJ; García-Borreguero D; Falone M; Winkelman JW Sleep; 2024 Jul; 47(7):. PubMed ID: 38625730 [TBL] [Abstract][Full Text] [Related]
4. Investigating the response to intravenous iron in restless legs syndrome: an observational study. Hornyak M; Scholz H; Kiemen A; Kassubek J Sleep Med; 2012 Jun; 13(6):732-5. PubMed ID: 22503006 [TBL] [Abstract][Full Text] [Related]
5. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327 [TBL] [Abstract][Full Text] [Related]
6. Ferric carboxymaltose in patients with heart failure and iron deficiency. Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P; N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome. Cho YW; Allen RP; Earley CJ Sleep Med; 2018 Feb; 42():7-12. PubMed ID: 29458749 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment for restless legs symptoms and low serum ferritin in children with autism spectrum disorder. DelRosso LM; Reuter-Yuill LM; Cho Y; Ferri R; Mogavero MP; Picchietti DL Sleep Med; 2022 Dec; 100():488-493. PubMed ID: 36265207 [TBL] [Abstract][Full Text] [Related]
9. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial. Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH; JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237 [TBL] [Abstract][Full Text] [Related]
10. Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. Bae H; Cho YW; Kim KT; Allen RP; Earley CJ Sleep Med; 2021 Aug; 84():179-186. PubMed ID: 34157632 [TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Cho YW; Allen RP; Earley CJ Sleep Med; 2016 Sep; 25():16-23. PubMed ID: 27823710 [TBL] [Abstract][Full Text] [Related]
12. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Lyseng-Williamson KA; Keating GM Drugs; 2009; 69(6):739-56. PubMed ID: 19405553 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Allen RP; Adler CH; Du W; Butcher A; Bregman DB; Earley CJ Sleep Med; 2011 Oct; 12(9):906-13. PubMed ID: 21978726 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of intravenous iron for patients with restless legs syndrome: evidence from randomized trials and observational studies. Yang X; Yang B; Ming M; Li S; Wang F; Zhu Z; Ji C; Long J; Hu F; Xu Z; Ren H; Liu B Sleep Med; 2019 Sep; 61():110-117. PubMed ID: 31395522 [TBL] [Abstract][Full Text] [Related]
15. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. Toblli JE; Di Gennaro F PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder. DelRosso LM; Ferri R; Chen ML; Kapoor V; Allen RP; Mogavero MP; Picchietti DL Sleep Med; 2021 Nov; 87():114-118. PubMed ID: 34562823 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Grote L; Leissner L; Hedner J; Ulfberg J Mov Disord; 2009 Jul; 24(10):1445-52. PubMed ID: 19489063 [TBL] [Abstract][Full Text] [Related]
18. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088 [TBL] [Abstract][Full Text] [Related]
19. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia. Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575 [TBL] [Abstract][Full Text] [Related]
20. Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome. Park HR; Choi SJ; Joo EY; Allen RP Sleep Med; 2020 Nov; 75():81-87. PubMed ID: 32853922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]